Sugi Predict

Sugi Predict / Compounds / SCHEMBL1630620

SCHEMBL1630620

SCHEMBL1630620

CNC(=O)[C@H](C)NC(=O)c1ccc(-c2ccccc2C#N)nc1NCCc1cccc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ CTSA P10619 1/20 0.37
▸ CNR2 P34972 2/20 0.36
▸ MMP1 P03956 2/20 0.35
▸ MMP13 P45452 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ RPS6KB1 P23443 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ CSNK2A2 P19784 2/20 0.34
▸ CSNK2A1 P68400 2/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ CASR P41180 1/20 0.33
▸ BRS3 P32247 1/20 0.33
▸ CTSB P07858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631302 1.00 KDM4E (0.40) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1630459 0.92 MEN1 (0.41) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632116 0.92 MEN1 (0.41) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631123 0.91 RPS6KB1 (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1629809 0.91 RPS6KB1 (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631695 0.91 CNR2 (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632372 0.91 CNR2 (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632908 0.91 NPC1 (0.38) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1630977 0.91 NPC1 (0.38) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632951 0.90 CNR2 (0.38) KDM4EMEN1MAPTKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 KDM4E 3309/4885MEN1 510/4885MAPT 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.